Get the Stockscreener App
13.44
0.98%
0.13
Elanco Animal Health Inc stock is traded at $13.44, with a volume of 2.14M.
It is up +0.98% in the last 24 hours and up +3.62% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$13.31
Open:
$13.29
24h Volume:
2.14M
Relative Volume:
0.49
Market Cap:
$6.64B
Revenue:
$4.49B
Net Income/Loss:
$-1.26B
P/E Ratio:
-67.20
EPS:
-0.2
Net Cash Flow:
$425.00M
1W Performance:
-5.29%
1M Performance:
+3.62%
6M Performance:
-20.94%
1Y Performance:
+13.13%
1-Day Range:
$13.17
$13.46
1-Week Range:
$13.15
$14.24
52-Week Range:
$11.40
$18.80
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ELAN | 13.44 | 6.64B | 4.49B | -1.26B | 425.00M | -0.20 |
| ZTS | 175.67 | 78.47B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.48 | 42.84B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.29 | 42.13B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.03 | 19.19B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.13 | 15.67B | 15.24B | -646.50M | 1.88B | 1.53 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Veterinary Medicine Market Future Business Opportunities 2024-2031 | Ceva, Zoetis, Elanco, Chanelle Pharma Group - openPR
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL
Just in time for Thanksgiving, SEC charges Elanco with undisclosed stuffing—channel stuffing, that is - JD Supra
Silent & Spreading: The Tapeworm Story Every Pet Owner Needs To Hear - ReportAlert.info
2024-11-20 | Shareholders that lost money on Elanco Animal Health Incorporated (ELAN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NYSE:ELAN | Press Release - Stockhouse Publishing
Companion Animal Arthritis Market Innovations in Treatment - openPR
Phocas Financial Corp. Sells 184,554 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Bragar Eagel & Squire Files Class Action Against Elanco Animal Health Incorporated for Securities Fraud - Lawyer Monthly Magazine
Elanco Animal Health Incorporated (ELAN) Q3 Earnings Top Estimates - MSN
רוזן, משרד עורכי דין מדורג ומוביל, מעודד משקיעים ב- Elanco Animal Health Incorporated לקבל ייעוץ לפני מועד חשוב בתביעה ייצוגית בניירות ערך – ELAN - GlobeNewswire Inc.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Elanco - GlobeNewswire
If You Lost Money on ELANCO ANIMAL HEALTH (ELAN) You Are Urged to Contact BFA Law About the Securities Fraud Class Action Lawsuit Before the Court Deadline Expires - Newsfile
Investors Who Lost Money With Elanco Animal Health Incorporated (NYSE:ELAN) Shares Should Contact the Shareholders Foundation in Connection With Lawsuit - AccessWire
LMR Partners LLP Has $4.91 Million Stake in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Equine Healthcare Market 2024 Projections, Trends, - openPR
Elanco (ELAN) Faces Federal Lawsuit Over Alleged Misrepresentation of Zenrelia's Safety Profile – Hagens Berman - GlobeNewswire
ELAN LEGAL DEADLINE: The Elanco Animal Health Securities - GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health - GlobeNewswire
Companion Animal Ear Infection Treatment Market Trends, - openPR
Animal Biotechnology Market to Continue Impressive Measured - openPR
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 6, 2024 in Elanco Animal Health Incorporated LawsuitELAN - PR Newswire
Animal Antibacterial and Antibiotics Market Analysis By Top - openPR
Elanco Faces Class Action Lawsuit Over Zenrelia Safety Claims, Launch Timeline | ELAN Stock News - StockTitan
ELAN FRAUD ALERT: Suffer Losses on Your Elanco Animal - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Elanco Animal - GlobeNewswire
Elanco Animal Health Inc. Class Action: Lead Plaintiff Deadline is December 6, 2024; Contact Robbins LLP for - EIN News
Elanco buys manufacturing facility in England for $25M - Indianapolis Business Journal
Elanco Acquires Speke Contract Manufacturing Facility, Securing Key Supply Chain - Pet Age
Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals - Simply Wall St
Elanco Animal Health's (NYSE:ELAN) Promising Earnings May Rest On Soft Foundations - Yahoo Finance
Elanco settles with SEC for $15M over alleged deception - AGDAILY
ELAN COURT ALERT: ELANCO ANIMAL HEALTH (ELAN) Investors that Suffered Losses are Alerted of a Pending Class ActionContact BFA Law before December 6 Court Deadline - AccessWire
Aquaculture Healthcare Market Worth Observing Growth | Elanco, Alltech, Benchmark Holdings - openPR
Europe Veterinary Orthopedics Market Expected to Reach $152 - openPR
Levi & Korsinsky Reminds Elanco Investors of the Pending | Trending From Our Network - Chicago Star Media
Elanco Animal Health Incorporated Investors: Please contact the Portnoy Law Firm to recover - The Bakersfield Californian
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health - PR Newswire
Elanco (ELAN) Faces Federal Lawsuit Over Alleged Misrepresentation of Zenrelia's Safety ... - The Bakersfield Californian
ELAN (Elanco Animal Health) EV-to-Revenue : 2.44 (As of Nov. 14, 2024) - GuruFocus.com
Investors in Elanco Animal Health Incorporated Should Contact The Gross Law Firm Before December 6, 2024 to Discuss Your RightsELAN - PR Newswire
Elanco (ELAN) Faces Federal Lawsuit Over Alleged Misrepresentation of Zenrelia's Safety Profile– Hagens Berman - GlobeNewswire
Elanco Animal Health Inc.'s SWOT analysis: stock outlook mixed amid product launches - Investing.com Australia
ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Lawsuit - Morningstar
Elanco settles SEC securities fraud suit for $15 million - FeedStrategy.com
Elanco Advances A Four-Pillar Livestock Sustainability Strategy - Drovers Magazine
Elanco Pays $15M SEC Fine To Settle Sales Incentive Claims - Law360
SEC Fines Elanco $15 Million Over Sales Incentive Practices - The Wall Street Journal
ELAN LEGAL ALERT: Elanco Animal Health (ELAN) was Sued for FraudInvestors are Urged to Contact BFA Law by December 6 Court Deadline - AccessWire
Elanco Animal Health Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Elanco Animal Health Incorporated Provides Earnings Guidance for the Fourth Quarter 2024 - Marketscreener.com
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):